CIARRA APPLIANCES has been focusing on the kitchen appliance market in Europe and America since its inception. CIARRA will not stop: making full use of the influence of online brands and starting to deploy offline, combining online and offline channels, and gradually building a complete sales operation system to achieve cost and service advantages. Build a multi-level logistics distribution system to create efficient logistics. Focusing on the needs of different scenarios in the kitchen, we continue to expand categories and continue to expand the growth margin of CIARRA.
Muse Technology is a one-stop online furniture retail and e-commerce platform for the purchase of indoor furniture.
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Dicerna Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative treatments primarily for liver-related diseases, including rare inherited conditions, chronic liver diseases, and viral infections. Utilizing its proprietary GalXC RNA interference technology, Dicerna focuses on silencing disease-causing genes to address various health issues. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and belcesiran for genetic liver disease, among others. The company's extensive research efforts also encompass treatments for cardiovascular diseases and neurodegeneration. Dicerna has established strategic collaborations with prominent pharmaceutical companies to enhance its development capabilities. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna is at the forefront of advancing RNA-based therapeutics.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was founded in 2008 and is headquartered in Santa Clara, California.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was founded in 2008 and is headquartered in Santa Clara, California.
Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at treating chronic pain while addressing the concerns of prescription drug abuse. The company utilizes its patented DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release profiles and safety of medications despite potential misuse methods such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an extended-release oral formulation of oxycodone designed to deter abuse, as well as Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol respectively, for managing severe pain and acute pain in adults. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions for patients with chronic pain, utilizing formulation improvements backed by strong intellectual property protections.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.
The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.
Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures.
The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was founded in 2008 and is headquartered in Santa Clara, California.
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Dicerna Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative treatments primarily for liver-related diseases, including rare inherited conditions, chronic liver diseases, and viral infections. Utilizing its proprietary GalXC RNA interference technology, Dicerna focuses on silencing disease-causing genes to address various health issues. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and belcesiran for genetic liver disease, among others. The company's extensive research efforts also encompass treatments for cardiovascular diseases and neurodegeneration. Dicerna has established strategic collaborations with prominent pharmaceutical companies to enhance its development capabilities. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna is at the forefront of advancing RNA-based therapeutics.
Crescendo Bioscience, Inc. is a molecular diagnostics company based in South San Francisco, California, specializing in the development of quantitative blood tests for autoimmune and inflammatory diseases, particularly rheumatoid arthritis (RA). Established in 2002, the company offers diagnostic, prognostic, staging, therapy selection, and monitoring tools designed to assist rheumatologists in managing patient care. One of its key products is Vectra DA, a standardized multi-biomarker blood test validated to evaluate disease activity in RA. By providing objective and quantitative molecular tests, Crescendo Bioscience aims to enhance clinical insights for rheumatologists and improve patient outcomes.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at treating chronic pain while addressing the concerns of prescription drug abuse. The company utilizes its patented DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release profiles and safety of medications despite potential misuse methods such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an extended-release oral formulation of oxycodone designed to deter abuse, as well as Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol respectively, for managing severe pain and acute pain in adults. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions for patients with chronic pain, utilizing formulation improvements backed by strong intellectual property protections.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was founded in 2008 and is headquartered in Santa Clara, California.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.
The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.
Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures.
The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was founded in 2008 and is headquartered in Santa Clara, California.
Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel antibiotics to combat serious multidrug-resistant infections. Its primary product candidate, Xerava (eravacycline), is a synthetic fluorocycline designed for intravenous use as a first-line treatment for multidrug-resistant infections, particularly those caused by Gram-negative bacteria. The company has conducted Phase III clinical trials, including IGNITE1 and IGNITE4, to evaluate Xerava's safety and efficacy for treating complicated intra-abdominal infections. In addition to Xerava, Tetraphase is advancing other product candidates, such as TP-271, which targets respiratory diseases caused by antibiotic-resistant pathogens, and TP-6076, aimed at treating multidrug-resistant Gram-negative infections. The company holds a licensing agreement with Everest Medicines Limited to develop and commercialize Xerava in various Asian markets. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase Pharmaceuticals is a subsidiary of La Jolla Pharmaceutical Company.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
Calibra Medical
Venture Round in 2009
Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.
Calypso Medical Technologies, based in Seattle, is a privately held medical device company specializing in tumor localization technology. The company's proprietary system employs miniaturized implanted devices known as Beacon electromagnetic transponders to continuously and accurately track the location of tumors, enhancing the precision and management of radiation therapy delivery. This technology is particularly aimed at body-wide cancers that are commonly treated with radiation. Calypso's products have received FDA 510(k) clearance for use in the prostate and post-operative prostatic bed, ensuring compliance with regulatory standards. The company has established strategic partnerships with leading organizations in the medical field, including Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical, to further its mission of improving cancer treatment outcomes.
Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel antibiotics to combat serious multidrug-resistant infections. Its primary product candidate, Xerava (eravacycline), is a synthetic fluorocycline designed for intravenous use as a first-line treatment for multidrug-resistant infections, particularly those caused by Gram-negative bacteria. The company has conducted Phase III clinical trials, including IGNITE1 and IGNITE4, to evaluate Xerava's safety and efficacy for treating complicated intra-abdominal infections. In addition to Xerava, Tetraphase is advancing other product candidates, such as TP-271, which targets respiratory diseases caused by antibiotic-resistant pathogens, and TP-6076, aimed at treating multidrug-resistant Gram-negative infections. The company holds a licensing agreement with Everest Medicines Limited to develop and commercialize Xerava in various Asian markets. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase Pharmaceuticals is a subsidiary of La Jolla Pharmaceutical Company.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.
The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.
Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures.
The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
SpinalMotion is dedicated to preserving motion in the spine for patients with degenerative disc disease. By developing innovative artificial discs and instrumentation, we seek to combine the kinematics of a mobile bearing design with materials designed for low wear and improved longevity. Building upon our international clinical experience since 2002, SpinalMotion obtained FDA approval to conduct lumbar and cervical artificial disc clinical trials in the United States in 2005. SpinalMotion is a private company founded in 2004 by Southern Medical, a spinal implant company in South Africa, and Thomas Weisel Healthcare partners. Three Arch Partners became an investor in 2005, and in 2006 Skyline Ventures and MedVenture Associates joined the company's investor group.
Mako Surgical is a medical device company that specializes in advanced robotic arm solutions and orthopedic implants for minimally invasive knee and hip procedures. The company is known for its flagship product, MAKOplasty, which provides a restorative surgical option for orthopedic surgeons to address early to mid-stage osteoarthritic conditions in patients. The core technology includes a robotic arm interactive orthopedic system that features a tactile robotic arm and an integrated bone cutting instrument, along with a visualization component that assists surgeons with pre-operative and intra-operative guidance. This innovative approach facilitates tissue-sparing bone removal and ensures precise implant insertion and alignment. Founded in 2004 and headquartered in Florida, Mako Surgical has gained recognition for its rapid growth and commitment to customer service in the medical technology sector.
Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel antibiotics to combat serious multidrug-resistant infections. Its primary product candidate, Xerava (eravacycline), is a synthetic fluorocycline designed for intravenous use as a first-line treatment for multidrug-resistant infections, particularly those caused by Gram-negative bacteria. The company has conducted Phase III clinical trials, including IGNITE1 and IGNITE4, to evaluate Xerava's safety and efficacy for treating complicated intra-abdominal infections. In addition to Xerava, Tetraphase is advancing other product candidates, such as TP-271, which targets respiratory diseases caused by antibiotic-resistant pathogens, and TP-6076, aimed at treating multidrug-resistant Gram-negative infections. The company holds a licensing agreement with Everest Medicines Limited to develop and commercialize Xerava in various Asian markets. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase Pharmaceuticals is a subsidiary of La Jolla Pharmaceutical Company.
InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity.
Calibra Medical
Series B in 2008
Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.
Dicerna Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative treatments primarily for liver-related diseases, including rare inherited conditions, chronic liver diseases, and viral infections. Utilizing its proprietary GalXC RNA interference technology, Dicerna focuses on silencing disease-causing genes to address various health issues. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and belcesiran for genetic liver disease, among others. The company's extensive research efforts also encompass treatments for cardiovascular diseases and neurodegeneration. Dicerna has established strategic collaborations with prominent pharmaceutical companies to enhance its development capabilities. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna is at the forefront of advancing RNA-based therapeutics.
At NovaSys Health they value your participation as a contracted provider. Roughly 11,000 providers in this region and over 4,300 providers in Arkansas have contracted with NovaSys Health making it one of the largest health plans in Arkansas. They take pride in the relationships that they have cultivated with providers.
$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.
Concert Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, founded in 2006. The company focuses on discovering and developing novel small-molecule drugs primarily for autoimmune and central nervous system disorders. Its key product candidates include CTP-543, currently in Phase III trials for alopecia areata; CTP-692, in Phase II trials for schizophrenia; and AVP-786, which is undergoing Phase III trials for various neurologic and psychiatric conditions, including agitation related to Alzheimer’s disease. Concert employs a unique precision deuterium chemistry platform to modify existing drug molecules, aiming to enhance efficacy and safety while reducing research and development risks. The company also maintains strategic collaborations with several pharmaceutical partners to further its research and development efforts.
Sequel Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes novel and clinical-stage drug candidates for patients with cardiovascular disease. The company was founded in 2007 and is based in San Diego, California.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.
The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.
Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures.
The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
Medivance, Inc. develops, manufactures, and sells temperature management products to hospitals worldwide. The company’s flagship product, the Arctic Sun Temperature Management System, enables clinicians to manage patient temperature in a noninvasive manner. It also offers clinical training in Targeted Temperature Management. The company was founded in 1998 and is headquartered in Louisville, Colorado with a European office in Den Hague, the Netherlands. As of November 10, 2011, Medivance, Inc. operates as a subsidiary of Bard Medical, Inc.
Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety, Inc. was founded in 2000 through a collaboration of medical device incubators Thomas Fogarty Engineering and The Foundry, and is headquartered in Palo Alto, California.
ARCA biopharma, Inc. is a Colorado-based biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. ARCA’s principal focus is to develop personalized therapies for the treatment of cardiovascular disease through the use of genetics. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development.
NovaCardia
Series B in 2007
NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.
Map Pharmaceuticals, Inc. is a development-stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, designed for migraine relief. Additionally, Map Pharmaceuticals is developing MAP0005 for adolescent and adult asthma and chronic obstructive pulmonary disease, as well as MAP0001, which targets Type 1 and Type 2 diabetes through pulmonary delivery via its Tempo inhaler. The company's focus is on delivering innovative treatments to improve patient outcomes across various health conditions.
Targanta Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative antibiotics aimed at treating serious infections encountered in hospitals and institutional settings. The company focuses on addressing gram-positive bacterial infections, particularly complicated skin and skin structure infections. By concentrating on these critical areas, Targanta Therapeutics seeks to enhance the efficacy of treatment options available for healthcare providers managing severe infections.
Concert Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, founded in 2006. The company focuses on discovering and developing novel small-molecule drugs primarily for autoimmune and central nervous system disorders. Its key product candidates include CTP-543, currently in Phase III trials for alopecia areata; CTP-692, in Phase II trials for schizophrenia; and AVP-786, which is undergoing Phase III trials for various neurologic and psychiatric conditions, including agitation related to Alzheimer’s disease. Concert employs a unique precision deuterium chemistry platform to modify existing drug molecules, aiming to enhance efficacy and safety while reducing research and development risks. The company also maintains strategic collaborations with several pharmaceutical partners to further its research and development efforts.
Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel antibiotics to combat serious multidrug-resistant infections. Its primary product candidate, Xerava (eravacycline), is a synthetic fluorocycline designed for intravenous use as a first-line treatment for multidrug-resistant infections, particularly those caused by Gram-negative bacteria. The company has conducted Phase III clinical trials, including IGNITE1 and IGNITE4, to evaluate Xerava's safety and efficacy for treating complicated intra-abdominal infections. In addition to Xerava, Tetraphase is advancing other product candidates, such as TP-271, which targets respiratory diseases caused by antibiotic-resistant pathogens, and TP-6076, aimed at treating multidrug-resistant Gram-negative infections. The company holds a licensing agreement with Everest Medicines Limited to develop and commercialize Xerava in various Asian markets. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase Pharmaceuticals is a subsidiary of La Jolla Pharmaceutical Company.
Tolerx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2000. The company specializes in developing novel therapies that modulate T-cell activities for the treatment of autoimmune diseases, diabetes, and cancer. Among its notable products is otelixizumab, a targeted T-cell immunomodulator designed specifically for type 1 diabetes. Additionally, Tolerx is advancing MTRX1011A, an anti-CD4 antibody aimed at various autoimmune conditions, as well as pre-clinical candidates TRX518 and TRX385, which focus on enhancing immune responses for cancer and chronic viral diseases.
NovaCardia
Series B in 2006
NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.
Concert Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, founded in 2006. The company focuses on discovering and developing novel small-molecule drugs primarily for autoimmune and central nervous system disorders. Its key product candidates include CTP-543, currently in Phase III trials for alopecia areata; CTP-692, in Phase II trials for schizophrenia; and AVP-786, which is undergoing Phase III trials for various neurologic and psychiatric conditions, including agitation related to Alzheimer’s disease. Concert employs a unique precision deuterium chemistry platform to modify existing drug molecules, aiming to enhance efficacy and safety while reducing research and development risks. The company also maintains strategic collaborations with several pharmaceutical partners to further its research and development efforts.
Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California.
KAI Pharmaceuticals is a drug discovery and development company focused on creating innovative therapeutics for cardiovascular disease, kidney disease, and pain management. The company's lead product candidate, KAI-9803, is undergoing a Phase 2b clinical trial aimed at evaluating its ability to reduce myocardial injury in patients experiencing heart attacks. Additionally, KAI is advancing its second core program, KAI-4169, which targets secondary hyperparathyroidism in kidney disease patients and is anticipated to enter human clinical trials. The company is also exploring pain management through its ongoing program, KAI-1678, currently in Phase 2a testing.
Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.
The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.
Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures.
The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
Map Pharmaceuticals, Inc. is a development-stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, designed for migraine relief. Additionally, Map Pharmaceuticals is developing MAP0005 for adolescent and adult asthma and chronic obstructive pulmonary disease, as well as MAP0001, which targets Type 1 and Type 2 diabetes through pulmonary delivery via its Tempo inhaler. The company's focus is on delivering innovative treatments to improve patient outcomes across various health conditions.
Hansen Medical, Inc. develops and manufactures advanced medical robotics focused on the precise positioning, manipulation, and control of catheters and catheter-based technologies. The company offers several key products, including the Sensei systems and Artisan Control Catheters, which are utilized during electrophysiology procedures to enhance the control and placement of mapping catheters. Additionally, Hansen Medical provides the CoHesion 3D Visualization Module, a software tool that aids physicians in catheter navigation with enhanced three-dimensional visual feedback. The Magellan Robotic System is another significant offering, featuring a robotically steerable catheter that allows for remote navigation and therapeutic device delivery. Hansen Medical markets its products through a combination of direct sales, distributors, and sales representatives. Founded in 2002 and based in Mountain View, California, the company is a subsidiary of Auris Surgical Robotics, Inc.
Guava Technologies, Inc. is a biotechnology and medical device company specializing in the development and manufacturing of flow cytometry systems. Founded in 1998 and headquartered in Hayward, California, the company provides a range of products designed for applications in cell biology research, drug discovery, and clinical diagnostics, with a specific focus on HIV/AIDS monitoring. Its offerings include assays for cell counting and viability, antibody quantification, apoptosis, cell cycle, cytotoxicity, and cell proliferation. Guava Technologies serves various markets, including life science research and core flow cytometry, contributing to advancements in cellular analysis. The company operates as a subsidiary of Millipore Corp.
iBalance Medical, Inc is a privately held medical device company located in Boulder, Colorado. Their focus is in advancing principles and surgical methods for the treatment of joint malalignment. Their initial development centers on providing a reproducible and predictable solution for knee malalignment.
Receptor Biologix develops receptor-based biological therapeutics for cancer, inflammatory, and autoimmune diseases. The company is headquartered in Palo Alto, California.
Tolerx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2000. The company specializes in developing novel therapies that modulate T-cell activities for the treatment of autoimmune diseases, diabetes, and cancer. Among its notable products is otelixizumab, a targeted T-cell immunomodulator designed specifically for type 1 diabetes. Additionally, Tolerx is advancing MTRX1011A, an anti-CD4 antibody aimed at various autoimmune conditions, as well as pre-clinical candidates TRX518 and TRX385, which focus on enhancing immune responses for cancer and chronic viral diseases.
Sirtris Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of proprietary, orally available small molecule drugs aimed at treating diseases related to aging. The company's research primarily focuses on metabolic disorders, including Type 2 Diabetes. By leveraging innovative approaches in drug development, Sirtris seeks to address the growing healthcare challenges associated with age-related diseases.
Sirtris Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of proprietary, orally available small molecule drugs aimed at treating diseases related to aging. The company's research primarily focuses on metabolic disorders, including Type 2 Diabetes. By leveraging innovative approaches in drug development, Sirtris seeks to address the growing healthcare challenges associated with age-related diseases.
Map Pharmaceuticals, Inc. is a development-stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, designed for migraine relief. Additionally, Map Pharmaceuticals is developing MAP0005 for adolescent and adult asthma and chronic obstructive pulmonary disease, as well as MAP0001, which targets Type 1 and Type 2 diabetes through pulmonary delivery via its Tempo inhaler. The company's focus is on delivering innovative treatments to improve patient outcomes across various health conditions.
KAI Pharmaceuticals is a drug discovery and development company focused on creating innovative therapeutics for cardiovascular disease, kidney disease, and pain management. The company's lead product candidate, KAI-9803, is undergoing a Phase 2b clinical trial aimed at evaluating its ability to reduce myocardial injury in patients experiencing heart attacks. Additionally, KAI is advancing its second core program, KAI-4169, which targets secondary hyperparathyroidism in kidney disease patients and is anticipated to enter human clinical trials. The company is also exploring pain management through its ongoing program, KAI-1678, currently in Phase 2a testing.
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company is advancing several product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials, and achromatopsia, currently in Phase I/II trials. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal disease. The company has also initiated a preclinical program in otology and three preclinical programs targeting central nervous system disorders such as frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. Collaborations with various organizations, including Synpromics Limited and the University of Florida, support its research efforts. Founded in 1999 and based in Alachua, Florida, AGTC employs advanced gene therapy techniques, aiming to replace defective genes with functional ones, thus improving patient outcomes with long-lasting treatments.
Roche NimbleGen specializes in providing a range of products and services for the life science research market, particularly in DNA sequencing and microarray technology. The company offers the SeqCap EZ system, which allows for exome enrichment in a single test tube, along with various design options and reagents to facilitate workflow. Additionally, Roche NimbleGen has developed the SeqCap Epi system for DNA methylation assessment at single-base resolution, and it supplies preparation and adapter kits for library construction. Their proprietary Maskless Array Synthesis technology enables the creation of custom high-density DNA arrays, enhancing the quality and data yield of sequencing efforts. The company also provides a suite of DNA microarray products for applications such as comparative genomic hybridization and gene expression analysis, alongside technical support services. Founded in 1999 and based in Madison, Wisconsin, Roche NimbleGen operates as a subsidiary of Roche Holding AG.
Alteer
Venture Round in 2002
Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging.
Advion is a global company headquartered in New York that specializes in the development of biochemistry analysis equipment. Founded in 1993, it offers a range of systems and consumables tailored for life science research. Advion's product portfolio includes chemist-centric mass spectrometers, nanoelectrospray ionization sources, and flow-chemistry synthesis systems. The company serves a diverse clientele comprising pharmaceutical firms, government life science research agencies, and academic institutions, focusing on the biopharmaceutical and industrial chemistry sectors.
Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.
Tolerx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2000. The company specializes in developing novel therapies that modulate T-cell activities for the treatment of autoimmune diseases, diabetes, and cancer. Among its notable products is otelixizumab, a targeted T-cell immunomodulator designed specifically for type 1 diabetes. Additionally, Tolerx is advancing MTRX1011A, an anti-CD4 antibody aimed at various autoimmune conditions, as well as pre-clinical candidates TRX518 and TRX385, which focus on enhancing immune responses for cancer and chronic viral diseases.
Roche NimbleGen specializes in providing a range of products and services for the life science research market, particularly in DNA sequencing and microarray technology. The company offers the SeqCap EZ system, which allows for exome enrichment in a single test tube, along with various design options and reagents to facilitate workflow. Additionally, Roche NimbleGen has developed the SeqCap Epi system for DNA methylation assessment at single-base resolution, and it supplies preparation and adapter kits for library construction. Their proprietary Maskless Array Synthesis technology enables the creation of custom high-density DNA arrays, enhancing the quality and data yield of sequencing efforts. The company also provides a suite of DNA microarray products for applications such as comparative genomic hybridization and gene expression analysis, alongside technical support services. Founded in 1999 and based in Madison, Wisconsin, Roche NimbleGen operates as a subsidiary of Roche Holding AG.
Guava Technologies, Inc. is a biotechnology and medical device company specializing in the development and manufacturing of flow cytometry systems. Founded in 1998 and headquartered in Hayward, California, the company provides a range of products designed for applications in cell biology research, drug discovery, and clinical diagnostics, with a specific focus on HIV/AIDS monitoring. Its offerings include assays for cell counting and viability, antibody quantification, apoptosis, cell cycle, cytotoxicity, and cell proliferation. Guava Technologies serves various markets, including life science research and core flow cytometry, contributing to advancements in cellular analysis. The company operates as a subsidiary of Millipore Corp.
Medivance, Inc. develops, manufactures, and sells temperature management products to hospitals worldwide. The company’s flagship product, the Arctic Sun Temperature Management System, enables clinicians to manage patient temperature in a noninvasive manner. It also offers clinical training in Targeted Temperature Management. The company was founded in 1998 and is headquartered in Louisville, Colorado with a European office in Den Hague, the Netherlands. As of November 10, 2011, Medivance, Inc. operates as a subsidiary of Bard Medical, Inc.
iScribe is a healthcare technology company that is focused on the development of mobile, handheld, and wireless electronic prescribing technology solutions. iScribe was founded by David Levison in 1999.
XenoPort, Inc. is a biopharmaceutical company that develops and commercializes treatments for neurological and other disorders. The company's primary product, HORIZANT (gabapentin enacarbil), is an extended-release tablet approved for the treatment of moderate-to-severe primary restless legs syndrome and postherpetic neuralgia in adults in the United States. XenoPort is advancing several other product candidates, including XP23829, which is in Phase III clinical trials for psoriasis and relapsing forms of multiple sclerosis, and arbaclofen placarbil, currently in Phase II trials for spasticity associated with multiple sclerosis. Additionally, XP21279, a potential treatment for advanced idiopathic Parkinson’s disease, has completed Phase II trials. XenoPort has established licensing and collaboration agreements with Indivior PLC, Astellas Pharma Inc., and Glaxo Group Limited for the development and commercialization of its products. Founded in 1999 and based in Santa Clara, California, XenoPort became a subsidiary of Arbor Pharmaceuticals, LLC as of July 2016.
Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.
Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.